The World Health Organization is taking the drug-testing approach that helped stifle Ebola's latest resurgence and using it against COVID-19, reported Bloomberg.
According to the news source, at least 10 countries including France, Spain and Switzerland have agreed to join the Solidarity trial that the WHO is coordinating, simultaneously testing four therapies by pitting them against each other.
In the Solidarity programme, researchers will test Gilead Sciences' experimental drug remdesivir, AbbVie's HIV drug Kaletra, Kaletra with the anti-inflammatory interferon-beta, and the malaria drug chloroquine.
"Multiple small trials with different methodologies may not give us the clear, strong evidence we need about which treatments help to save lives," WHO Director-General Tedros Adhanom Ghebreyesus said.
Argentina, Bahrain, Canada, Iran, Norway, South Africa and Thailand have also agreed to participate in the coronavirus trials, Tedros said.
In the Ebola trials, researchers compared the impact of several drugs including remdesivir. When a therapy by Regeneron Pharmaceuticals showed clear superiority against the deadly infection, the study was stopped early so the medicine could be given to more patients.
To read more NewsPoints articles, click here.